Premium
Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer
Author(s) -
Read Rebecca L.,
Flitcroft Kathy,
Snook Kylie L.,
Boyle Frances M.,
Spillane Andrew J.
Publication year - 2015
Publication title -
anz journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.426
H-Index - 70
eISSN - 1445-2197
pISSN - 1445-1433
DOI - 10.1111/ans.12975
Subject(s) - medicine , cosmesis , breast cancer , axilla , chemotherapy , neoadjuvant therapy , oncology , breast conserving surgery , adjuvant , cancer , intensive care medicine , surgery , mastectomy
Neoadjuvant chemotherapy ( NAC ) is a legitimate alternative to first‐line surgical therapy for the treatment of breast cancer patients, as level one evidence shows the effect on overall survival is equivalent to that of adjuvant chemotherapy. In the treatment of women with operable breast cancer, NAC provides a number of potential advantages including: improving the chance of achieving breast‐conserving surgery, improving cosmesis after breast‐conserving surgery, downstaging the breast and axilla, allowing time to fully consider surgical options, time for genetic testing and facilitating breast reconstruction in otherwise high‐risk patients. However, in A ustralia, NAC is poorly utilized with less than 3% of women with operable breast cancer receiving NAC . This review discusses the potential harms and benefits of NAC , discusses areas of controversy in the use of NAC and describes how we have used NAC in our own practice. We conclude that if it is obviously necessary for the newly presenting breast cancer patient to have chemotherapy as part of the treatment, it is worth considering NAC . In many patients, the potential benefits of NAC outweigh the harms. However, maximizing these benefits is closely aligned with appropriate patient selection and timely multidisciplinary team communication.